Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

Daniel Perez-Zsolt; Itziar Erkizia; Maria Pino; Mónica García-Gallo; Maria Teresa Martin; Susana Benet; Jakub Chojnacki; María Teresa Fernández-Figueras; Dolores Guerrero; Victor Urrea; Xabier Muñiz-Trabudua; Leonor Kremer; Javier Martinez-Picado; Nuria Izquierdo-Useros

doi:10.1038/s41564-019-0453-2

Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

Daniel Perez-Zsolt, Itziar Erkizia, Maria Pino, Mónica García-Gallo, Maria Teresa Martin, Susana Benet, Jakub Chojnacki, María Teresa Fernández-Figueras, Dolores Guerrero, Victor Urrea, Xabier Muñiz-Trabudua, Leonor Kremer, Javier Martinez-Picado, Nuria Izquierdo-Useros

Producció científica: Contribució a revista › Article › Recerca

50 Cites (Scopus)

Resum

© 2019, The Author(s), under exclusive licence to Springer Nature Limited. Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.

Idioma original	Anglès
Pàgines (de-a)	1558-1570
Nombre de pàgines	13
Revista	Nature Microbiology
Volum	4
Número	9
DOIs	https://doi.org/10.1038/s41564-019-0453-2
Estat de la publicació	Publicada - 3 de juny 2019

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

ODG 3 – Bona salut i benestar

Accés al document

10.1038/s41564-019-0453-2

Altres arxius i enllaços

Com citar-ho

Perez-Zsolt, D., Erkizia, I., Pino, M., García-Gallo, M., Martin, M. T., Benet, S., Chojnacki, J., Fernández-Figueras, M. T., Guerrero, D., Urrea, V., Muñiz-Trabudua, X., Kremer, L., Martinez-Picado, J., & Izquierdo-Useros, N. (2019). Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry. Nature Microbiology, 4(9), 1558-1570. https://doi.org/10.1038/s41564-019-0453-2

@article{d06268bfafe04c7899ff8a4a4986c1fb,

title = "Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry",

abstract = "{\textcopyright} 2019, The Author(s), under exclusive licence to Springer Nature Limited. Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.",

author = "Daniel Perez-Zsolt and Itziar Erkizia and Maria Pino and M{\'o}nica Garc{\'i}a-Gallo and Martin, \{Maria Teresa\} and Susana Benet and Jakub Chojnacki and Fern{\'a}ndez-Figueras, \{Mar{\'i}a Teresa\} and Dolores Guerrero and Victor Urrea and Xabier Mu{\~n}iz-Trabudua and Leonor Kremer and Javier Martinez-Picado and Nuria Izquierdo-Useros",

year = "2019",

month = jun,

day = "3",

doi = "10.1038/s41564-019-0453-2",

language = "English",

volume = "4",

pages = "1558--1570",

journal = "Nature Microbiology",

issn = "2058-5276",

publisher = "Nature Research",

number = "9",

}

Perez-Zsolt, D, Erkizia, I, Pino, M, García-Gallo, M, Martin, MT, Benet, S, Chojnacki, J, Fernández-Figueras, MT, Guerrero, D, Urrea, V, Muñiz-Trabudua, X, Kremer, L, Martinez-Picado, J & Izquierdo-Useros, N 2019, 'Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry', Nature Microbiology, vol. 4, núm. 9, pàg. 1558-1570. https://doi.org/10.1038/s41564-019-0453-2

TY - JOUR

T1 - Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

AU - Perez-Zsolt, Daniel

AU - Erkizia, Itziar

AU - Pino, Maria

AU - García-Gallo, Mónica

AU - Martin, Maria Teresa

AU - Benet, Susana

AU - Chojnacki, Jakub

AU - Fernández-Figueras, María Teresa

AU - Guerrero, Dolores

AU - Urrea, Victor

AU - Muñiz-Trabudua, Xabier

AU - Kremer, Leonor

AU - Martinez-Picado, Javier

AU - Izquierdo-Useros, Nuria

PY - 2019/6/3

Y1 - 2019/6/3

N2 - © 2019, The Author(s), under exclusive licence to Springer Nature Limited. Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.

AB - © 2019, The Author(s), under exclusive licence to Springer Nature Limited. Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.

UR - http://www.mendeley.com/research/antisiglec1-antibodies-block-ebola-viral-uptake-decrease-cytoplasmic-viral-entry

UR - https://www.scopus.com/pages/publications/85067016278

U2 - 10.1038/s41564-019-0453-2

DO - 10.1038/s41564-019-0453-2

M3 - Article

C2 - 31160823

SN - 2058-5276

VL - 4

SP - 1558

EP - 1570

JO - Nature Microbiology

JF - Nature Microbiology

IS - 9

ER -

Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho